TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual...
-
Upload
iris-harrington -
Category
Documents
-
view
215 -
download
1
Transcript of TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual...
![Page 1: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/1.jpg)
TARIQ ALASBALI
![Page 2: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/2.jpg)
Glaucoma: Treatment Goal
“The goal of glaucoma treatment is to
preserve the visual field of patients
and prevent the loss of visual function
associated with the disease.”
Ref: Survey of Ophthalmology; 2003 Vol. 48(1): S1-S3
![Page 3: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/3.jpg)
What is a target IOP?
“The IOP at which the rate of retinal ganglion cell loss is no greater
than the age related loss.”Brubaker
![Page 4: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/4.jpg)
AAO Guidelines: Target IOP
30
40
30
20
05
10152025303540
MildDamage
AdvanceDamage
NTG OHT
% r
educ
tion
from
bas
elin
e
Ref: Survey of Ophthalmology 2003; 48 (suppl 1); 53-57
![Page 5: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/5.jpg)
Target IOP is based on over-all glaucomatous damage
![Page 6: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/6.jpg)
Not only controlling peak IOP is important but the drug should also control fluctuations in IOP
REQUIREMENT OF AN AGENT
FOR PROVEN 24-HOUR CONTROL
![Page 7: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/7.jpg)
In POAG what is your first line drug and why?
What are your next choices?
![Page 8: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/8.jpg)
PG/PAPG/PA
Target Not AchievedTarget Not Achieved
EffectiveEffectiveNot at TargetNot at Target
Target Achieved:Target Achieved:Continue to FollowContinue to Follow
Beta-BlockerBeta-Blockeraa
BrimonidineBrimonidineaa
Topical CAITopical CAIaa
CholinergicCholinergicbb
Oral CAIOral CAIbb
a: Order depends a: Order depends on side effects & on side effects & contraindications contraindications
b: Secondary Drugs b: Secondary Drugs Consider other Consider other therapies alsotherapies also
Continue & Return to Top Continue & Return to Top with Additional Drugwith Additional Drug
Ineffective Or Side effectIneffective Or Side effect
Discontinue & Return to Top Discontinue & Return to Top with Different Drugwith Different Drug
![Page 9: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/9.jpg)
Primary Drug Classes
Prostaglandin Analogues / Prostamides
Beta Adrenergic Antagonists ‘Beta blockers’
Alpha 2 Adrenergic Agonists
Carbonic Anhydrase Inhibitors
![Page 10: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/10.jpg)
Primary Drug Classes
A meta-analysis of 27 articles suggests that bimatoprost, travoprost, latanoprost, and timolol are the most effective intraocular pressure-reducing agents in POAG and OH patients.
Ophthalmology. 2005 Jul;112(7):1177-85 .
![Page 11: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/11.jpg)
Prostaglandin Analogues is approved by
(FDA), as a first line treatment for elevated
(IOP) associated with open angle glaucoma
or ocular hypertension
http://www. medscape.com assessed on 18/11/03
![Page 12: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/12.jpg)
Secondary Drug Classes
Parasympathomimetics Cholinergic (Muscarinic) Agonists Acetylcholinesterase inhibitors
Non-selective Adrenergic Agonists Rarely used
![Page 13: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/13.jpg)
Drug classDrug classMedicationMedicationMean ↓IOP Mean ↓IOP % ↓IOP% ↓IOP
PGAPGALatanoprostLatanoprost
BimatoprostBimatoprost
TravoprostTravoprost
6-8 mm Hg6-8 mm Hg
7-8 mm Hg7-8 mm Hg
7-8 mm Hg7-8 mm Hg
~ 30%~ 30%
B-blocker, non B-blocker, non selectiveselective
TimololTimolol~6mm Hg~6mm Hg~25%~25%
A-2 adrenergicA-2 adrenergicBrimonidineBrimonidine2-6 mm Hg2-6 mm Hg20-25%20-25%
B-blocker, B-blocker, selectiveselective
BetaxololBetaxolol4-5 mm Hg4-5 mm Hg~20%~20%
CAICAIDorzolamideDorzolamide3-5 mm Hg3-5 mm Hg15-20%15-20%
![Page 14: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/14.jpg)
Prostaglandin Analogues & Prostamides: Dosing & Preparations Latanoprost
Travoprost Bimatoprost
All QHS
![Page 15: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/15.jpg)
Latanoprost: Instillation at 9 pm
0
Baseline
Latanoprost
27
25
23
21
19
17
15
15 18 2121 24 03 06 09 12
Time (hours)
IOP
)m
mH
g(
Latanoprost when instilled at 9 pm effective controlled IOP at 9 am Peak IOP
![Page 16: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/16.jpg)
Prostaglandin Analogues & Prostamides: Mechanism of Action Increase uveoscleral outflow
At least 8 PG receptor subtypes
Latanoprost and Travoprost analogues of PGF2α bind known PG receptors
Whether Bimatoprost works in the same way seems to depend on whether you work for Allergan or Pfizer
![Page 17: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/17.jpg)
Prostaglandin Analogues & Prostamides: Mechanism of Action
Free acid is active component at PG receptors
Requires enzymatic cleavage
Latanoprost and Travoprost are esters
Esterases present in cornea and a.c.
Bimatoprost is an amide.
![Page 18: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/18.jpg)
Prostaglandin Analogues & Prostamides: IOP Response Expected IOP lowering:
~30%
Latan = Trav=Bim (1) Another finding difference, generally < 1mmHg (2)
Recent Meta-Analysis (3) Latan: 31% peak, 28% trough Trav: 31 % peak, 29% trough Bim: 33 % peak, 28% trough
Onset of IOP lowering 2-4 hours
Peak Effect 8-12 hours
Wash Out 4-6 weeks
1-Clin Experiment Ophthalmol. 2006:34(8):755-64.1-Clin Experiment Ophthalmol. 2006:34(8):755-64. 2-Adv Ther. 2004 Jul-Aug;21(4):247-62.2-Adv Ther. 2004 Jul-Aug;21(4):247-62. 3-Ophthalmology.2005:112(7):1177-11853-Ophthalmology.2005:112(7):1177-1185
![Page 19: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/19.jpg)
PROSTAGLANDIN: Proven for 24 hour IOP Control
Ref: Invest Ophthalmol Vis Sci 2000; 41: 2566-2573
27
25
23
21
19
17
15
015 18 2121 24 03 06 09 12
Tim e (hou rs)
B ase line
Tim o lo l tw ice da ily
La tanop rost
D o rzolom ide th ree tim es dailyIO
P (
mm
Hg
)
Latanoprost, travoprost, and bimatoprost were effective in reducing the 24-h IOP in patients with XFS and OH
Eye (2007) 21, 453–458
![Page 20: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/20.jpg)
Prostaglandin Analogues & Prostamides: Interactions with Other IOP drugs
Theoretically expected to have poor additivity with parasympathomimetics
Clinically, this has not been proven
Good additivity to others
![Page 21: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/21.jpg)
Prostaglandin Analogues & Prostamides: Side Effects
Lash Changes
Pigmentation Iris Periocular skin
Pro-Inflammatory Hyperemia of Conjunctiva Uveitis CME
Reactiviation of HSV keratitis
![Page 22: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/22.jpg)
Beta-Blocker Preparations
Non-selective Timolol 0.25%, 0.5%
Gel-vehicle (Timoptic XE 0.25%, 0.5%) Levobunolol 0.25%, 0.5%
Befunolol Metipranolol
Beta 1 Selective Betaxolol 0.25%, 0.5%
![Page 23: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/23.jpg)
Beta-Blocker Preparations
With ISA Cartelol 0.5% - 2% Pindolol 2%
![Page 24: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/24.jpg)
Beta Blockers: Mechanism of Action
Mediated through beta 2 adrenergic receptors
Decreases aqueous production
![Page 25: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/25.jpg)
Beta Blockers: Dosing
BID dosing except gel-vehicle Increasing beyond BID of no help
Timoptic XE once daily in a.m.
![Page 26: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/26.jpg)
Beta Blockers: IOP Response
Expected IOP lowering: ~25%
Peak effect Two hours
Wash out 2-5 weeks
![Page 27: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/27.jpg)
Beta Blockers
Use w/ systemic β-blocker:• No additional effect on pulse or BP
• ↓ IOP lowering with ↑ oral dose
• Use of systemic β-blocker can mask prior IOP elevation and cause pseudo-NTG picture
![Page 28: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/28.jpg)
Beta-Blockers
Carteolol 1% Intrinsic sympathomimetic activity
• Theoretically causes less bronchoconstriction, bradycardia, vasoconstriction
• Less ocular irritation• Better tolerated in dry eye patients
![Page 29: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/29.jpg)
Beta-Blockers
Betagan ® Levobunolol 0.25%, 0.5%• Slightly longer half-life than timolol; ? qd
dosage
Betoptic-S® (betaxolol 0.25% ): β1-selective
• Less pulmonary and CNS side effects• Less systemic absorption than timolol
![Page 30: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/30.jpg)
Beta Blockers: Side Effects Bronchospasm
Bradycardia, arrhythmia
CHF
Syncope
Hypotension
Depression
Sexual dysfunction
![Page 31: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/31.jpg)
Beta-Blockers: Contraindications
Asthma (Reactive Airway Disease)
Bradycardia
Heart block
Acute CHF
![Page 32: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/32.jpg)
Iopidine® (apraclonidine 0.5%, 1%)
BID-TID
- α1, α2
Decreases aqueous production
May lose efficacy after 4-6 months
Alphagan-P® (brimonidine 0.1%, 0.15%), generic brimonidine 0.2%
BID-TID - α2-selective
↓aqueous production; ↑uveoscleral outflow
May lose efficacy after 1 year
Neuroprotection?
Alpha 2 Agonists:Dosing & Preparations
![Page 33: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/33.jpg)
BRIMONIDINE :THE NEUROPROTECTIVE 2 AGONIST
Brimonidine neuroprotection may be mediated
through up-regulation of Brain-derived
neurotrophic factor BDNF in the retinal
ganglion cells RGCs.
Brimonidine may be (potentially) used
clinically as a neuroprotective agent.
Arch Ophthalmol. 2002;120:797-803.
![Page 34: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/34.jpg)
Alpha 2 Agonists: IOP Response
Expected IOP lowering: 20-25%
Peak Effect 2 hours
Wash Out 1-3 weeks
![Page 35: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/35.jpg)
Alpha 2 Agonists: IOP Response A recent study conclude that
Brimonidine 0.2% has a higher potency of lowering IOP than brimonidine Purite 0.15% at trough when used twice-daily.
However, ocular allergic reaction was more frequent and severe with brimonidine 0.2% than with brimonidine Purite 0.15%.
Journal of Ocular Pharmacology and Therapeutics. 2007, 23(5): 481-486.
![Page 36: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/36.jpg)
Alpha 2 Agonists: IOP Response
One study suggests: brimonidine purite BID= dorzolamide
BID
???
British Journal of Ophthalmology 2004;88:953-956
![Page 37: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/37.jpg)
Alpha 2 Agonists: Side Effects Follicular conjunctivitis
50% apraclonidine 15% (at least) brimonidine Less with Alphagan P
Need more non-pharmaceutical company data
Fatigue, drowsiness Eye lid retraction Dry mouth Hypotension
![Page 38: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/38.jpg)
Alpha 2 Agonists: Side Effects
Apnea in infants and young children
weight > 20 Kg age > 6 Years Alternative glaucoma therapy should
be considered.
OphthalmologyOphthalmology Volume 112, Issue 12Volume 112, Issue 12, December 2005, December 2005
![Page 39: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/39.jpg)
CAIs : Dosing & Preparations Topical
Trusopt® Dorzolamide 2%: BID – TID Azopt® Brinzolamide 1%: BID – TID
Oral Diamox® Acetazolamide: 250mg QID, SR
500 BID Neptazane® Methazolamide: 50-100mg
Once/Day-TID
![Page 40: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/40.jpg)
CAIs: Mechanism of Action
Inhibit CA enzyme in ciliary body epithelium
Decrease aqueous production
Improve ocular blood flow?
![Page 41: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/41.jpg)
Topical CAIs : IOP Response
Expected IOP lowering: 15-20%
Wash Out Topical: 1 week Oral: 3 days
![Page 42: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/42.jpg)
Topical CAIs : Side Effects
Ocular surface irritation Contact allergy
Contraindication: Sulfonamide allergy
![Page 43: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/43.jpg)
Oral CAIs: Side Effects Paresthesias
Tinnitus
Depression
Loss of appetite
GI symptoms
Kidney stones
Metabolic acidosis
Electrolyte imbalance
![Page 44: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/44.jpg)
Oral CAIs: Side Effects
Anaphylaxis
Stevens-Johnson Syndrome
Bone marrow dysfunction Idiosyncratic Can be any cell line
aplastic anemia most described Some reversible some not Potentially lethal
![Page 45: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/45.jpg)
CAIs
Oral is additive to topical (1-2mmHg) Topical not additive to oral
Methazolamide 75% liver metabolized Safer in renal disease
Eg. Diabetic with CRF and NVG
![Page 46: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/46.jpg)
Parasympathomimetics: Dosing & Preparations
Pilocarpine 0.5% - 4% BID-QID 4% gel once daily (QHS)
Carbachol 0.75% - 3% BID-TID
![Page 47: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/47.jpg)
Parasympathomimetics: Mechanism of Action
Increase TM outflow
Believed secondary to contraction of smooth muscle fibers inserting into scleral spur
![Page 48: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/48.jpg)
Parasympathomimetics: IOP Response
Expected IOP lowering: 10-20 %
Lowers IOP by 1 hour post instillation
Wash Out: 3 days
![Page 49: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/49.jpg)
Parasympathomimetics: Side Effects Pro-inflammatory
Break down blood ocular barrier Miosis
Brow ache (<~40 y.o.) P.S.
Shallowing of A.C. Possible worsening of pupil block
RD Cataract
![Page 50: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/50.jpg)
Fixed CombinationCosopt
CombiganXalacom DuoTrav Ganfort
![Page 51: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/51.jpg)
Fixed Combination
XALACOM QD = TIMOLOL BID + XALATAN QHS (1)
XALACOM QD > COSOPT BID (2)
XALACOM QD > BRIMONIDINE BID +
TIMOLO BID (3)
1-Ophthalmology. 2006 Jan;113(1):70-62-Ophthalmology. 2004 Feb;111(2):276-8.
33--Acta Ophthalmol Scand. 2003 Jun;81(3):242-6Acta Ophthalmol Scand. 2003 Jun;81(3):242-6
![Page 52: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/52.jpg)
Fixed Combination Martinez et all study showed a
significantly higher IOP-lowering effect of a once-daily evening dose of the BTFC compared to that of a once-daily evening administration of the LTFC. (1)
(1) Current Medical Research and Opinion, Volume 23, Number 5, May 2007 , pp. 1025-1032(8) (1) Current Medical Research and Opinion, Volume 23, Number 5, May 2007 , pp. 1025-1032(8)
![Page 53: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/53.jpg)
EXAMPLE
Abstract conclusion:
Bimatoprost provided greater mean IOP reduction than travoprost.
Br J Ophthalmology 2006; 90:1370-1373Br J Ophthalmology 2006; 90:1370-1373..
Main outcome measureMain outcome measure To evaluate the efficacies of bimatoprost and travoprost for To evaluate the efficacies of bimatoprost and travoprost for lowering of IOP for the treatment of glaucoma and ocular HTN.lowering of IOP for the treatment of glaucoma and ocular HTN.
ResultResult:: The mean reduction in the bimatoprost group were The mean reduction in the bimatoprost group were
greater than the reduction in the travoprost group at greater than the reduction in the travoprost group at every study visit, but theseevery study visit, but these
differences were not significant (p >0.207)differences were not significant (p >0.207)..
![Page 54: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/54.jpg)
COMPLIANCE: THE HIDDEN CHALLENGE OF GLAUCOMA
MANAGEMENT
![Page 55: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/55.jpg)
Patient Compliance: GlaucomaPatient compliance is a particularly
important issue in glaucoma because: Asymptomatic Long term therapy Benefit of treatment not apparent Several medications Expense of treatment Inconvenience of treatment Side effects of treatment
Ref: J of Glaucoma 1992; 1: 134-136
![Page 56: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/56.jpg)
Patient Non-compliance: Glaucoma
Available literature suggests that between 28% and 58% of glaucoma patients do not use their medications as prescribed
Non compliance is probably 30%-40%
Ref: http://www.escrs.org/April 2003 assessed on 27/03/04
![Page 57: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/57.jpg)
Adv Ther. 2001 Sep-Oct;18(5):205-15.
BAK has demonstrated cytotoxic effects in cell culture, as well as in animal and human studies.
Physicians should consider treatment with new-generation preparations containing low-risk preservatives, especially in patients receiving multiple ophthalmic medications.
PreservativesPreservatives
![Page 58: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/58.jpg)
Preservatives
A study on rats corneas suggest that glaucoma medications with low levels of BAK, alternative preservatives such as Purite®, or preservative-free formulations are more benign to the ocular surfaces.
Cornea. 2004 Jul;23(5):490-6. Cornea. 2004 Jul;23(5):490-6.
![Page 59: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/59.jpg)
British Journal of Ophthalmology423-418-86-2002:
Preservatives
![Page 60: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/60.jpg)
Preservatives
Alphagan P Purite Alphagan 0,005% Lumigan 0,005% Combigan 0.005% Trusopt 0.0075% Cosopt 0.0075% Azopt 0.01% Timoptic 0.01% Betoptic 0.01% Travatan 0.015% Xalatan 0.02% Xalacom 0.02 %
![Page 61: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/61.jpg)
A Little Perspective…
“The risk and cost, including side effects of treatment to lower pressure, must be weighed against
the risk of pressure itself.”Hodapp
![Page 62: TARIQ ALASBALI. Glaucoma: Treatment Goal “The goal of glaucoma treatment is to preserve the visual field of patients and prevent the loss of visual function.](https://reader030.fdocuments.us/reader030/viewer/2022032414/56649ee75503460f94bf7930/html5/thumbnails/62.jpg)
If you light a lamp for somebody , It will also brighten your path